PBRM1 and nonpapillary renal cell carcinoma: However, in a recent randomized phase II study of metastatic ccRCC, no association was seen between presence of PBRM1 mutations and treatment response to the PD-L1-directed atezolizumab, nor to the combination of atezolizumab plus bevacizumab (n = 136); there was a favorable effect on treatment response in patients receiving sunitinib (anti-VEGF) on the control arm of the same study (n = 72)4.